dengu
viru
denv
mosquitoborn
pathogen
impos
maximum
burden
economi
public
health
larg
part
america
southeast
asia
africa
accord
recent
estim
close
million
symptomat
case
occur
everi
year
overal
econom
burden
dengu
nearli
billion
vaccin
develop
effort
result
introduct
firstev
dengu
viru
vaccin
human
use
mani
countri
promis
vaccin
candid
advanc
stage
clinic
trial
nevertheless
lack
signific
progress
antivir
develop
dengu
viru
number
compound
identifi
dengu
viru
inhibitor
use
vitro
silico
approach
compound
advanc
clinic
trial
human
chloroquin
celgosivir
balapiravir
drug
reach
clinicaltri
stage
howev
result
report
studi
clinicaltrialsgov
registr
number
respect
repurpos
drug
one
way
fasttrack
antivir
discoveri
build
preexist
knowledg
candid
drug
case
drug
proven
safe
human
use
condit
process
help
bring
drug
human
use
faster
new
candid
drug
accord
industri
estim
take
year
discoveri
therapeut
use
drugrepurpos
effort
yield
first
antiretrovir
zidovudin
origin
evalu
anticanc
drug
approv
treatment
hivaid
gemcitabin
nucleosid
analog
use
cancer
treatment
shown
inhibit
mani
virus
screen
effort
fdaapprov
compound
led
identif
compound
activ
middl
east
respiratori
syndrom
coronaviru
merscov
sever
acut
respiratori
syndrom
coronaviru
sarscov
studi
encourag
us
use
approach
screen
librari
pharmacolog
activ
compound
antidengu
viru
compound
cover
major
pharmacolog
relev
target
class
mani
approv
drug
human
use
thu
provid
excel
platform
repurpos
antivir
studi
report
screen
dengu
viru
inhibitor
use
imagingbas
screen
approach
cell
identifi
three
inhibitor
librari
specif
block
earli
stage
dengu
viru
rna
replic
data
underscor
valu
econom
benefit
drugreposit
effort
could
har
augment
antivir
pipelin
cell
japanes
enceph
viru
jev
west
nile
viru
wnv
isol
viru
growth
condit
procedur
determin
titer
describ
previous
see
supplement
materi
detail
dengu
viru
infect
inhibitor
treatment
experi
perform
cell
viral
titer
cultur
supernat
determin
plaqu
assay
cell
inhibitori
concentr
experi
perform
use
dilut
inhibitor
start
concentr
total
cell
plate
plate
infect
multipl
infect
moi
incub
dulbecco
modifi
eagl
medium
dmem
contain
inhibitor
supernat
collect
h
postinfect
pi
viral
titer
estim
plaqu
assay
cell
western
blot
cell
lysat
prepar
describ
previous
inhibitor
treatment
condit
describ
membran
probe
antibodi
recogn
denv
nonstructur
protein
kind
gift
raj
bhatnagar
tubulin
monoclon
development
studi
hybridoma
bank
calnexin
thermo
fisher
glucoseregul
protein
bd
bioscienc
antibodi
detect
antibodi
high
specif
form
use
cell
signal
technolog
signal
detect
chemiluminesc
see
supplement
materi
descript
flow
cytometri
experi
twenti
millilit
infect
cultur
supernat
concentr
use
amicon
ultra
concentr
cutoff
merckmillipor
rna
isol
concentr
supernat
use
trizol
thermo
fisher
scientif
aqueou
phase
obtain
chloroform
step
mix
rna
bind
buffer
process
rna
isol
use
rna
clean
concentr
kit
zymo
research
total
ng
rna
transfect
cell
use
lipofectamin
thermo
fisher
scientif
h
posttransfect
medium
contain
dimethyl
sulfoxid
dmso
inhibitor
ad
h
postinfect
total
rna
isol
describ
amount
denv
negativestrand
rna
estim
describ
total
rna
isol
cell
use
either
trizol
quickrna
microprep
kit
zymo
research
denv
rna
level
estim
describ
previous
use
taqman
onestep
realtim
pcr
appli
biosystem
amount
denv
negativestrand
rna
measur
cdna
synthesi
forward
primer
follow
realtim
pcr
use
primescript
rt
reagent
kit
genom
dna
gdna
eras
takara
primerprob
mix
appli
biosystem
use
normal
fold
chang
calcul
method
cell
grown
coverslip
plate
infect
treat
inhibitor
describ
h
pi
cell
process
immunofluoresc
visual
doublestrand
rna
dsrna
describ
previous
assess
effect
inhibitor
endolysosom
marker
cell
treat
inhibitor
describ
h
cell
fix
stain
antibodi
earli
endosom
antigen
bd
bioscienc
lysosomeassoci
membran
glycoprotein
development
studi
hybridoma
bank
follow
secondari
antibodi
conjug
alexa
imag
acquir
object
use
olympu
ix
invert
fluoresc
microscop
imag
process
background
correct
use
olympu
fluoview
softwar
z
project
imag
shown
graphpad
prism
softwar
use
graphic
represent
statist
analys
experi
perform
two
three
replic
sampl
result
figur
compil
data
experi
perform
least
two
three
time
p
valu
estim
mannwhitney
test
oneway
analysi
varianc
anova
screen
use
highthroughput
screen
reduct
number
virusinfect
cell
determin
fluoresc
imag
assay
reduct
viral
titer
supernat
use
endpoint
cell
infect
treat
either
inhibitor
dmso
control
cell
stain
denv
e
antibodi
infect
cell
visual
use
cell
analyz
imag
platform
identifi
compound
primari
hit
show
inhibit
denv
infect
confirm
inhibitori
activ
compound
secondari
screen
use
two
independ
assay
measur
viral
titer
supernat
plaqu
assay
ii
viral
rna
level
h
pi
cell
treat
inhibitor
see
fig
supplement
materi
base
secondari
screen
select
three
inhibitor
ndesmethylclozapin
fluoxetin
hydrochlorid
salmeterol
xinafo
consist
show
inhibit
viral
titer
viral
rna
level
without
cytotox
effect
see
fig
supplement
materi
next
confirm
whether
inhibitor
effect
flavivirus
close
relat
denv
japanes
enceph
viru
west
nile
viru
cell
infect
jev
wnv
viru
titer
estim
h
pi
surprisingli
none
three
inhibitor
effect
either
jev
wnv
titer
see
fig
supplement
materi
confirm
observ
inhibit
denv
infect
specif
cell
infect
cell
treat
cell
inhibitor
describ
viral
titer
supernat
estim
plaqu
assay
h
pi
cell
fix
stain
denv
e
antibodi
percentag
denvposit
cell
analyz
fluorescenceactiv
cell
sorter
fac
analysi
observ
complet
absenc
virusposit
cell
viral
titer
supernat
cell
treat
inhibitor
compar
dmso
fig
f
result
suggest
inhibitor
act
denv
cell
typeindepend
manner
next
perform
inhibit
experi
cell
infect
respiratori
syncyti
viru
rsv
negativestrand
rna
viru
proport
cell
posit
rsv
antigen
determin
fac
analysi
antibodi
rsv
fusion
f
protein
h
pi
contrast
denv
infect
none
inhibitor
effect
rsv
infect
observ
rsv
posit
fac
analysi
dmso
inhibitortr
cell
see
fig
supplement
materi
rel
rsv
genom
level
measur
rtpcr
similarli
fac
result
effect
inhibitor
rsv
genom
level
see
fig
supplement
materi
verifi
specif
inhibitor
test
effect
three
inhibitor
rotaviru
rv
infect
cell
infect
rotaviru
doublestrand
rna
viru
treat
inhibitor
describ
cultur
supernat
collect
h
pi
viral
titer
measur
plaqu
assay
case
rsv
none
inhibitor
signific
effect
rotaviru
titer
see
fig
supplement
materi
result
indic
inhibitor
specif
denv
may
directli
affect
denv
infect
block
one
viral
protein
target
host
pathway
specif
util
denv
next
perform
inhibit
experi
cell
deriv
aed
albopictu
mosquito
surprisingli
inhibitor
effect
denv
titer
cell
see
fig
supplement
materi
suggest
inhibitor
may
target
factor
pathway
express
cell
human
origin
next
determin
ndesmethylclozapin
fluoxetin
salmeterol
cell
infect
cell
infect
treat
increas
concentr
inhibitor
viral
titer
measur
plaqu
assay
h
pi
ndesmethylclozapin
fluoxetin
hydrochlorid
salmeterol
xinafo
respect
fig
c
verifi
stage
viral
life
cycl
affect
addit
inhibitor
prepar
total
cell
lysat
h
pi
cell
infect
denv
treat
dmso
inhibitor
viral
infect
detect
perform
western
blot
analysi
denv
level
reduc
cell
treat
three
inhibitor
compar
dmso
treatment
suggest
inhibitor
act
stage
prior
viral
protein
translat
fig
next
determin
denv
genom
level
h
pi
realtim
pcr
total
rna
isol
denvinfect
cell
treat
dmso
inhibitor
found
denv
rna
level
reduc
three
inhibitor
fig
inhibitor
ad
viru
entri
cell
experi
inhibit
like
occur
stage
either
viral
uncoat
translat
viral
rna
input
viru
rna
replic
next
perform
inhibit
experi
cell
stain
dsrna
intermedi
viral
replic
dsrna
detect
infect
cell
treat
dmso
inhibitortr
cell
mockinfect
cell
fig
furthermor
measur
level
negativestrand
rna
intermedi
h
pi
denvinfect
cell
treat
inhibitor
ndesmethylclozapinetr
cell
show
reduct
negativestrand
rna
level
salmeterol
fluoxetinetr
cell
negativestrand
rna
dmsotreat
cell
fig
result
demonstr
three
inhibitor
act
earli
stage
dengu
viru
rna
replic
next
assess
whether
inhibitor
capabl
block
postrepl
stage
viral
life
cycl
cell
infect
denv
inhibitor
ad
h
postinfect
viral
titer
measur
plaqu
assay
h
postinfect
time
addit
h
h
postinfect
time
addit
h
addit
inhibitor
inhibitori
h
postinfect
wherea
h
postinfect
effect
fig
h
postinfect
expect
later
stage
viral
life
cycl
name
viral
genom
packag
assembl
egress
activ
compar
viral
rna
replic
therefor
inhibitor
block
viral
rna
replic
would
effect
stage
viral
infect
togeth
data
clearli
suggest
three
inhibitor
block
earli
stage
viral
life
cycl
abl
prevent
viru
infect
viru
enter
postrepl
stage
infect
demonstr
effect
inhibitor
postentri
stage
transfect
cell
rna
prepar
infect
cell
cultur
supernat
follow
incub
medium
contain
dmso
inhibitor
total
rna
prepar
transfect
cell
h
posttransfect
amount
negativestrand
rna
measur
rtpcr
observ
reduct
amount
negativestrand
rna
inhibitortr
sampl
compar
dmso
treatment
fig
data
clearli
show
inhibitor
act
one
stage
postviru
entri
name
membran
fusion
uncoat
initi
rna
replic
intern
denv
shown
undergo
membran
fusion
late
endosom
compart
therefor
next
investig
whether
treatment
inhibitor
effect
endolysosom
pathway
cell
treat
inhibitor
h
stain
earli
endosom
late
endosomelysosom
marker
treatment
three
inhibitor
effect
distribut
howev
stain
drastic
differ
cell
treat
inhibitor
fig
three
inhibitor
induc
robust
enlarg
late
endosomeslysosom
h
treatment
indic
possibl
disrupt
endolysosom
function
thu
affect
earli
stage
viral
fusion
uncoat
replic
addit
assess
whether
treatment
inhibitor
induc
stress
respons
pathway
unfold
protein
respons
autophagi
immunofluoresc
western
blot
analys
first
verifi
induct
autophagi
stain
cell
treat
inhibitor
wellestablish
marker
autophagi
induct
stain
undetect
dmsotreat
cell
treatment
inhibitor
clearli
show
presenc
structur
fig
next
prepar
total
cell
lysat
cell
treat
inhibitor
describ
verifi
induct
autophagi
cell
treat
inhibitor
show
mark
increas
level
marker
autophagi
wherea
amount
cellular
chaperon
name
calnexin
remain
unchang
fig
next
investig
whether
inhibitor
capabl
induc
autophagi
context
denv
infect
observ
treatment
three
compound
dmso
led
cleavag
detect
band
mockinfect
denvinfect
lysat
fig
note
denv
infect
lead
induct
autophagi
measur
detect
infect
condit
data
suggest
three
inhibitor
denv
replic
induc
autophagi
may
act
antivir
respons
block
earli
stage
dengu
viru
infect
identifi
three
compound
ndesmethylclozapin
fluoxetin
hydrochlorid
salmeterol
xinafo
dengu
viru
replic
inhibitor
denv
screen
assay
three
inhibitor
reduc
dengu
viru
infect
highnanomolarlowmicromolar
rang
cell
treat
inhibitor
low
level
dsrna
negativestrand
intermedi
find
along
timeofaddit
rna
transfect
experi
demonstr
inhibitor
interf
earli
stage
dengu
viru
rna
replic
effect
specif
dengu
viru
inhibitor
effect
relat
flavivirus
jev
wnv
respiratori
syncyti
viru
negativestrand
rna
viru
rotaviru
viru
doublestrand
rna
genom
final
show
treatment
three
inhibitor
led
lysosom
enlarg
autophagosom
format
possibl
affect
endolysosom
pathway
specif
involv
earli
stage
denv
life
cycl
although
number
studi
character
directact
antivir
target
dengu
viru
protein
mani
cellular
factor
also
identifi
propos
target
antivir
develop
two
drug
identifi
studi
ndesmethylclozapin
fluoxetin
regul
serotonin
receptor
signal
howev
recent
studi
demonstr
inhibit
earli
stage
dengu
viru
replic
antagonist
dopamin
receptor
serotonin
receptor
therefor
inhibitori
effect
ndesmethylclozapin
fluoxetin
unlik
due
direct
effect
serotonin
receptor
signal
previou
report
show
inhibit
autophagosom
turnov
impair
lysosom
fusion
clozapin
cortic
neuron
rat
fluoxetin
shown
induc
endoplasm
reticulum
er
stress
respons
autophagi
certain
cancer
cell
line
concentr
use
studi
treatment
murin
macrophag
day
variou
concentr
fluoxetin
show
cytotox
inhibit
mycobacterium
tuberculosi
growth
concentrationdepend
manner
primarili
induc
autophagi
via
induct
tumor
necrosi
factor
alpha
administr
fluoxetin
also
led
induct
inflammatori
cytokin
mous
frontal
cortex
similarli
observ
show
cell
treatment
condit
induct
autophagi
er
stress
measur
level
inflammatori
cytokin
secret
treatment
inhibitor
studi
unlik
inflammatori
mediat
would
specif
alter
denv
infect
without
affect
mani
rna
virus
test
studi
specul
inhibitor
identifi
studi
target
pathway
involv
endolysosom
biogenesi
thu
affect
fusion
intern
dengu
viru
virion
late
endosom
membran
inhibitor
target
host
factor
requir
dengu
viru
uncoat
andor
initi
genom
replic
previou
studi
shown
rsv
rv
induc
autophagi
later
stage
infect
rsv
infect
dendrit
cell
induc
autophagi
shown
essenti
product
innat
cytokin
alpha
interferon
abrog
autophag
pathway
neg
affect
rotaviru
titer
suggest
autophagi
may
restrict
viral
replic
induct
innat
immun
respons
case
may
also
hijack
famili
virus
provid
replic
advantag
role
autophagi
life
cycl
flavivirus
jev
wnv
controversi
case
denv
recent
report
demonstr
differenti
regul
autophagi
pathway
denv
cours
infect
autophagi
shown
support
denv
replic
earli
stage
play
antivir
role
later
stage
denv
suppress
pathway
later
stage
infect
observ
induct
autophagi
infect
condit
probabl
due
suppress
effect
singleparticletrack
studi
shown
denv
coloc
autophagosom
endocytosi
undergo
fusion
late
endosom
specul
treatment
ndesmethylclozapin
fluoxetin
salmeterol
lead
alter
autophagosomelysosom
biogenesi
affect
earli
stage
denv
life
cycl
observ
also
hint
differ
pathway
use
relat
flavivirus
earli
stage
infect
ndesmethylclozapin
major
metabolit
clozapin
potent
serotonin
receptor
antagonist
clozapin
antipsychot
drug
salmeterol
receptor
agonist
antiinflammatori
properti
conjunct
corticosteroid
salmeterol
current
prescrib
bronchodil
patient
chronic
obstruct
pulmonari
diseas
copd
persist
asthma
fluoxetin
select
serotonin
reuptak
inhibitor
use
antidepress
report
antivir
activ
compound
fluoxetin
shown
previous
inhibit
hepat
c
viru
infect
cell
block
product
reactiv
oxygen
speci
lipid
accumul
fluoxetin
also
identifi
inhibitor
coxsackieviru
replic
studi
shown
inhibit
viral
replic
viral
entri
translat
viral
genom
fluoxetin
identifi
anoth
antivir
screen
studi
inhibitor
human
enteroviru
b
replic
evalu
fluoxetin
potenti
therapeut
option
enteroviru
acut
flaccid
myeliti
describ
previous
test
abil
ndesmethylclozapin
salmeterol
inhibit
enterovirus
like
inhibitor
identifi
studi
may
affect
pathway
common
denv
enterovirus
character
host
factor
involv
earli
stage
denv
infect
similar
enteroviru
life
cycl
would
help
identifi
antivir
target
work
silico
dock
known
structur
dengu
viru
protein
gener
resist
virus
would
provid
clue
respect
abil
inhibitor
directli
affect
dengu
viru
replic
believ
studi
provid
new
use
compound
approv
human
use
condit
safeti
profil
efficaci
drug
need
valid
pilot
trial
dengu
virusinfect
patient
drug
would
use
virem
phase
infect
shorter
period
human
believ
side
effect
observ
prolongeddos
regimen
condit
may
pertin
viral
infect
final
drug
inhibit
dengu
viru
replic
via
cellular
target
identif
molecular
target
would
help
develop
safer
potent
antivir
dengu
viru
